Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Significance of Ficolin 2 in the Determination of Serological Activity in Chronic Inflammatory Bowel Disease

This study has been completed.
Sponsor:
Collaborators:
University Hospital, Basel, Switzerland
University of Lausanne Hospitals
Swiss IBD Cohort Study
MSD Merck Sharp & Dohme AG
Information provided by:
University of Bern
ClinicalTrials.gov Identifier:
NCT01473927
First received: November 3, 2011
Last updated: March 11, 2014
Last verified: March 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2013
  Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)